Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.RSV.preF Vaccine in Older Japanese Adults
NCT04354480Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2020
- Primary completion
- Jan 2021
- Modality
- Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Ad26.RSV.preF in respiratory syncytial virus infection (RSV) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Solicited Local Adverse Events at 7 days, Number of Participants with Solicited Systemic Adverse Events at 7 days and 2 more. Started May 2020; status: completed.
02
Drugs
Ad26.RSV.preF
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04354480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04354480.